These observations support a role for FOXA1 as a regulator of prostate cancer plasticity, in part mediated by TGFβ signaling and supports a strategy to control these events and, potentially, to potentiate the clinical response to antiandrogen therapies [650]. Here, TGFB1 is linked to Familial prostate cancer.